Why Is CULLINAN THERAPEUTIC (CGEM) Stock Moving Today?

Cullinan Therapeutics (CGEM) fell 8.48% to $15.44 in the session as the company delayed the release of multi-dose data for its rheumatoid arthritis therapy, CLN-978. The update, originally expected in the third quarter, will now be available in December. The delay has raised concerns among investors about the drug’s safety profile and development timeline.

What Happened

The stock extended its losses after the company disclosed the delay in a recent filing and through public statements. The multi-dose data for CLN-978, which targets difficult-to-treat rheumatoid arthritis, was expected to provide early insights into the drug’s potential. The postponement has intensified scrutiny over the drug’s progress and its ability to meet regulatory and market expectations. Additionally, the company has faced lingering concerns over zipalertinib, its other key therapy, despite positive Phase 3 trial results for that drug in EGFR exon 20+ lung cancer. The mixed signals have contributed to the downward pressure on the stock.

What The Data Shows

Over the past eight trading sessions, CGEM has declined 23.7% from $20.40 to $15.57. The stock has printed 24 fresh 52-week lows on September 24, 2026, indicating significant retail and institutional selling pressure. Meanwhile, the Chief Scientific Officer, Jennifer Michaelson, has sold shares on three separate occasions over the past 90 days, totaling $923K. These insider sales reflect a lack of immediate confidence in the stock’s near-term direction. The company’s fundamentals remain weak, with a market cap of $1.4B and a trailing twelve-month earnings per share of -3.47.

What To Watch

Investors should monitor the December 2026 data readouts for CLN-978 across rheumatoid arthritis, SLE, and Sjögren’s disease. These updates will be critical in determining the drug’s potential and could influence the stock’s trajectory in the coming months.